Sign up to save your podcasts
Or
Share Endocrine Therapies in ER-Positive/HER2-Negative MBC: Understanding Their Benefits and Limitations to Optimize Treatment Selection
Share to email
Share to Facebook
Share to X
Share to email
Share to Facebook
Share to X
Or
Endocrine Therapies in ER-Positive/HER2-Negative MBC: Understanding Their Benefits and Limitations to Optimize Treatment Selection
Did you know that approximately 50% of breast cancer patients who have been exposed to an aromatase inhibitor (AI) over time in the metastatic setting develop an ESR1 mutation?
Credit available for this activity expires: 10/17/26 Earn Credit / Learning Objectives & Disclosures: https://www.medscape.org/viewarticle/1003008?ecd=bdc_podcast_libsyn_mscpedu
View all episodes
By Medscape
4.3
2525 ratings
Did you know that approximately 50% of breast cancer patients who have been exposed to an aromatase inhibitor (AI) over time in the metastatic setting develop an ESR1 mutation?
Credit available for this activity expires: 10/17/26 Earn Credit / Learning Objectives & Disclosures: https://www.medscape.org/viewarticle/1003008?ecd=bdc_podcast_libsyn_mscpedu
More shows like Keeping Current CME
View all
JAMA Editors' Summary
136 Listeners
AFP: American Family Physician Podcast
697 Listeners
JAMA Clinical Reviews
497 Listeners
JACC This Week
168 Listeners
Diabetes Core Update
103 Listeners
This Week in Cardiology
881 Listeners
The Bob Harrington Show
14 Listeners
One-on-One with Eric Topol
16 Listeners
Mayo Clinic Talks
291 Listeners
Frankly Speaking About Family Medicine
262 Listeners
The Curbsiders Internal Medicine Podcast
3,349 Listeners
Core IM | Internal Medicine Podcast
1,146 Listeners
Annals On Call Podcast
193 Listeners
JAMA Medical News
92 Listeners
The Clinical Problem Solvers
515 Listeners
Harrison's PodClass: Internal Medicine Cases and Board Prep
368 Listeners
Freely Filtered, a NephJC Podcast
172 Listeners
Medicine and the Machine
61 Listeners
Keeping Current
8 Listeners
Cardionerds: A Cardiology Podcast
426 Listeners